Table 3. Univariate and multivariate analysis for breast cancer-specific survival (Cox proportional hazards model).
| Variable |
Value | n | Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | ||||
| Age at operation | (ref = < 50) | 50 < | 344 | 1.54 | 0.61-4.60 | NS | NS | ||
| Menopause state | (ref = Pre) | Post | 342 | 1.50 | 0.60-4.50 | NS | NS | ||
| T stage | (ref = T1) | T2 < | 343 | 2.80 | 1.20-7.40 | 0.014* | 1.21 | 0.42-3.79 | NS |
| Node metastasis | (ref = 0) | Positive | 330 | 3.20 | 1.30-8.10 | 0.0065* | 3.92 | 1.44-11.8 | 0.0067 |
| Histopathology | (ref = Lobular) | Ductal | 312 | 0.25 | 0.07-1.60 | NS | NS | ||
| Nuclear Grade | (ref = 1,2) | 3 | 340 | 4.60 | 2.00-11.0 | 0.0004* | 1.49 | 0.53-4.33 | NS |
| ERα (IHC) | (ref = <1%) | 1% < | 344 | 0.12 | 0.05-0.29 | <0.0001* | 0.17 | 0.05-0.56 | 0.0032* |
| PgR (IHC) | (ref = <1%) | 1% < | 342 | 0.14 | 0.05-0.33 | <0.0001* | |||
| HER2 | (ref = Negative) | Positive | 344 | 0.58 | 0.09-2.00 | NS | NS | ||
| Ki67 (MIB1) | (ref = < 15%) | 15 < | 327 | 6.00 | 1.70-37.5 | 0.0021* | 3.30 | 0.91-21.1 | NS |
| AR | (ref = <1%) | 1% < | 338 | 0.17 | 0.07-0.41 | 0.0002* | 0.40 | 0.15-1.07 | NS |
| ERβ | (ref = the 25th percentile) | Positive | 295 | 0.61 | 0.25-1.50 | NS | NS | ||
| PA1 in the nucleus | (ref = the 25th percentile) | Positive | 344 | 0.60 | 0.26-1.40 | NS | NS | ||
| PA1 in the cytoplasm | (ref = the 25th percentile) | Positive | 344 | 0.91 | 0.39-2.00 | NS | NS | ||
| Systemic therapy | (ref = No) | Yes | 340 | 0.22 | 0.18-1.60 | NS | NS | ||
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; AR, androgen receptor; HR, Hazard Ratio; CI, Confidence Interval; NS, Not significant.
Considering the co-effect of PA1 expression with each factor was used in the multivariate analysis, respectively
* Factor showing statistical significance.